Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

82.13USD
8:05pm BST
Change (% chg)

$0.15 (+0.18%)
Prev Close
$81.98
Open
$81.98
Day's High
$83.77
Day's Low
$81.00
Volume
63,446
Avg. Vol
87,289
52-wk High
$83.77
52-wk Low
$45.05

Chart for

About

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $883.61
Shares Outstanding(Mil.): 15.17
Dividend: --
Yield (%): --

Financials

  EGRX.OQ Industry Sector
P/E (TTM): 9.78 30.93 32.76
EPS (TTM): 5.95 -- --
ROI: 64.07 15.07 14.61
ROE: 70.78 16.60 16.34

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE

16 May 2018

BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53

* EAGLE PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 RESULTS

10 May 2018

BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln

* EAGLE PHARMACEUTICALS INC SAYS CEO SCOTT TARRIFF'S 2017 TOTAL COMPENSATION WAS $8.04 MILLION VERSUS $7.15 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2HK04hV Further company coverage: (Reuters.Briefs@thomsonreuters.com)

30 Apr 2018

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

16 Apr 2018

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

27 Mar 2018

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

26 Feb 2018

Earnings vs. Estimates